New candidate of choice for diagnosing and preventing rubella

Discover how The Native Antigen Company is improving infectious disease management and looking ahead to the future at virus-like particle (VLP) vaccines, which offer a scalable and cost-effective alternative to traditional vaccines. Learn how rubella is set to benefit from the advancements of VLP vaccines, as rubella VLPs, developed through recombinant expression in HEK293 cells, offer a reliable solution by mimicking the virus’ structure and self-assembling into high-quality particles. Explore how these VLPs provide researchers with a consistent and efficient tool for vaccine production, research, and diagnostics.